RSS Content

AtriCure Announces Upcoming Investor Conference Schedule

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation at

AtriCure management is also scheduled to participate in the Barrington Research 7th Annual Fall Investment Conference at the Four Seasons Hotel in Chicago on September 4, 2014.

About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy Ablation System is the first and only surgical device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the LAA. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.

Source: AtriCure, Inc.

AtriCure, Inc.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer
Investor Relations Contact
Westwicke Partners
Lynn Pieper, 415-202-5678